1. Home
  2. GOSS vs HTD Comparison

GOSS vs HTD Comparison

Compare GOSS & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.72

Market Cap

796.2M

Sector

Health Care

ML Signal

HOLD

Logo John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HTD

John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$23.97

Market Cap

843.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
HTD
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
796.2M
843.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GOSS
HTD
Price
$2.72
$23.97
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.83
N/A
AVG Volume (30 Days)
4.6M
92.3K
Earning Date
03-12-2026
01-01-0001
Dividend Yield
N/A
8.59%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,051,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$16.17
52 Week High
$3.87
$22.13

Technical Indicators

Market Signals
Indicator
GOSS
HTD
Relative Strength Index (RSI) 46.08 51.96
Support Level $2.38 $23.77
Resistance Level $3.00 $24.25
Average True Range (ATR) 0.22 0.29
MACD 0.02 0.05
Stochastic Oscillator 56.24 70.69

Price Performance

Historical Comparison
GOSS
HTD

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.

Share on Social Networks: